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ABSTRACT 
 
This study investigated the role of muscle strength and voluntary activation (VA) on 
symptomatic fatigue in individuals with multiple sclerosis (MS). Nine women with relapsing-
remitting or secondary-progressive MS (mean age, 43yrs) were compared to nine healthy women 
(mean age, 37yrs). Symptomatic fatigue was assessed using the Modified Fatigue Impact Scale 
(MFIS), Fatigue Severity Scale, and Visual Analogue Fatigue Scale. Functional capacity was 
assessed with a 6-Minute Walk Test (6-MWT). Muscle strength and VA were determined using 
twitch interpolation applied to the right dorsiflexor muscles during maximal voluntary isometric 
contractions (MVIC). Muscle fatigue was assessed during a sustained submaximal contraction. 
Distance during the 6-MWT, muscle strength and VA were significantly lower in the MS group. 
MFIS scores were negatively associated with muscle strength and VA. The MS group was more 
easily fatigued, as measured by MVIC. In conclusion, symptomatic fatigue is associated with 
muscle fatigue and weakness in individuals with MS.  
 
 
 
 
 
 
Keywords: Multiple Sclerosis (MS); Interpolated twitch technique (ITT); Voluntary activation 
(VA); Symptomatic fatigue; Muscle strength; Fatigue 
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GLOSSARY OF TERMS 
 
Central nervous system (CNS)- a portion of the nervous system which includes the brain and 
spinal cord  
 
Kurtzke expanded disability status scale (EDSS)- clinical evaluation of quantifying disability 
in multiple sclerosis  
 
Neuromuscular fatigue- a reduction in muscle force production following exertion 
 
Fatigue- an overwhelming sense of exhaustion or tiredness that renders an individual from being 
able to initiate or complete an activity that he/she would normally be able to do 
 
Fatigue severity scale (FSS)- a self-administered questionnaire used to assess the severity of 
fatigue and the impact on daily functioning during the past week 
 
Interpolated twitch technique (ITT)- a technique used to assess the completeness of skeletal 
muscle activation 
 
Maximal voluntary isometric contraction (MVIC)- maximal effort voluntary contraction 
where the joint angle remains constant during the contraction 
 
Modified fatigue impact scale (MFIS)- a self-administered questionnaire used to assess the 
perceived impact of fatigue within the past four weeks 
 
Multiple sclerosis (MS)- non-traumatic central nervous system (brain and spinal cord) disorder 
 
Neuromuscular junction- a specialized synapse between a motor neuron and a muscle end-plate 
 
Peak torque- the maximum production of force about a vector (the dynamometer arm) for a 
single contraction, measured in newton.meters (Nm) 
 
Peripheral fatigue- a progressive reduction in force production resulting from fatigue occurring 
in the muscle distal to the neuromuscular junction 
 
Voluntary activation (VA)- the level of central drive achieved during a voluntary isometric 
contraction at any target force  
 
Visual analogue fatigue scale (VAFS)- a research instrument designed to measure an attribute 
that is best illustrated by a continuum of values versus discrete points 
 
Weakness- loss of strength within a given muscle independent of previous work or activity  
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CHAPTER 1 
 
FATIGUE IN THE NEUROMUSCULAR SYSTEM 
 
1.0 GENERAL INTRODUCTION  
 
1.01 Multiple Sclerosis 
Multiple sclerosis (MS) is the most common non-traumatic central nervous system (brain 
and spinal cord) disorder of young adulthood, affecting approximately 100,000 people in Canada 
and 2.5 million people worldwide [1–4]. The diagnosis of MS most commonly occurs in the 
second or third decade of life, with a female:male ratio of 2:1 [2–5]. Although the etiology of 
MS has yet to be clearly established, interactions between environmental, infectious, and genetic 
factors are currently considered as possible causes [6–9]. MS involves unpredictable episodes of 
axonal demyelination, resulting in lesions along axons of nerve fibers in the central nervous 
system (CNS) pathways [7]. The demyelination of the nerve fibers interferes with the neuronal 
conduction from the CNS to effector organs [7,10–13]. This interference manifests as various 
symptoms such as sensory loss, cognitive impairment, gait disturbance, visual impairment, 
bladder and bowel control, spasticity, weakness and fatigue [7,12,14].  
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Figure 1.1. Nerve Fibre (neuron) from a healthy individual and person with MS (with 
permission from Alexandra Lynette-Krech, (2017)) 
 
The clinical course of MS is characterized by acute periods of worsening (relapses), 
progressive deterioration of neurological function, or combinations of both [15]. Relapsing-
remitting MS (RRMS) is the most common disease course, affecting approximately 85% of 
individuals with MS [16]. This disease course manifests as a period of relapse followed by a 
period of remission, during which symptoms improve partially or completely [7,15]. Secondary-
progressive MS (SPMS) follows the initial RRMS disease course with a steady progression, with 
or without relapses [2,15,17]. Sixty percent of people who are initially diagnosed with RRMS 
will transition to SPMS [2,15]. Primary-progressive MS occurs in approximately 10% of 
individuals with MS, and is characterized by steadily worsening neurological function from the 
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onset, with no distinct relapses or remission [2,7,15]. Lastly, progressive-relapsing MS is the 
least common of the four disease courses, occurring in approximately 5% of individuals with 
MS, and is characterized by steadily progressing disease from the beginning with occasional 
relapses along the way [2,7]. The disease continues to progress without remissions. The pattern 
of clinical symptoms and descriptors is complex; the types are displayed in Fig 1.2.  
 
 
Figure 1.2. Clinical types of MS (with permission from Fred D. Lublin, M.D, (2016)) 
 
Therapies are a key component of MS care, along with treating symptoms and managing 
MS relapses. The approach to the treatment of MS is individualized to ones’ relative disabilities, 
needs, and support system.  
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There are currently 12 disease-modifying therapies (DMTs) that have been approved by 
Health Canada; seven are injectable, three are oral, and two are infused [2]. These are currently 
the best approach available to slow the natural course of MS [2]. DMTs target some aspect of the 
inflammatory process of MS while reducing the severity and frequency of relapses, the 
development of new lesions, and the progression of disability [2]. Both clinical experience and 
clinical investigation have suggested that early intervention with DMTs may help to prevent 
permanent damage in the CNS, increasing ones’ overall level of function and quality of life [2].  
The majority of current treatments for MS are pharmaceutical. However, due to the 
variability of MS symptoms, individuals often seek relief through rehabilitation and alternative 
medicine [2]. Rehabilitation specialists, such as physical therapy, occupational therapy, speech-
language pathology, vocational rehabilitation and cognitive rehabilitation provide evaluation and 
treatment to improve and maintain function [2,18]. Alternative medicine includes a wide variety 
of interventions from naturopathy to stress management and acupuncture, and are instrumental in 
the management of the disease[18]. As well, assistive devices (e.g. walkers, scooters, 
wheelchairs) and appropriate orthoses (e.g. ankle foot orthoses) should be considered as they 
play a viable role in the management of mobility [18].  
1.02 The Motor System  
The motor systems in the CNS control a multitude of functional outputs, both voluntary 
and involuntary [19]. The motor systems are organized in hierarchy from the cerebral cortex, 
brainstem to spinal cord, to peripheral motor system. The spinal cord is the lowest level in the 
CNS hierarchical structure, and conduits information through neuronal circuits that control 
various reflexes and rhythmic movement [20]. The brainstem is the middle level in the 
hierarchical structure, and contains neuronal circuits that mediate locomotion and orofacial 
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movement [20]. The cerebral cortex is the highest level in the hierarchical structure, housing the 
motor cortex [20]. The motor cortex consists of the primary motor cortex (M1), premotor area, 
and secondary motor areas, and are responsible for the planning, initiating, and execution of 
voluntary movement [20].  
Movement is initiated through motor commands from the M1 and premotor areas. 
Commands are transmitted down the corticospinal tract to the spinal cord via upper motor 
neurons (UMNs) [19,20]. Axons of UMNs synapse in the ventral horn of the spinal cord with 
lower motor neurons (LMNs) either directly or indirectly, via spinal interneurons [19]. LMN 
axons exit as the ventral root, and combine with the dorsal root to form the peripheral nerve [19]. 
Axons of the LMNs leave the CNS, forming peripheral axons and eventually branch distally near 
their target muscle to form a terminal arborization [19]. Each of the terminal branches form a 
synapse-like junction, known as the neuromuscular junction (NMJ), innervating skeletal muscle 
and thus initiating movement [19]. 
Motor system dysfunction can result from damage or disease at any level of the motor 
system hierarchy. Damage to the UMNs of the descending motor pathways results in the upper 
motor neuron syndrome, and gives rise to a set of signs and symptoms such as weakness, fatigue,  
positive Babinski sign, spasticity, hyperreflexia of superficial reflexes, and loss of dexterity 
[21,22]. These acute manifestations tend to be most severe in the arms and legs and would be 
seen in conditions such as cerebral palsy, primary lateral sclerosis, and multiple sclerosis. 
Damage to the LMNs of the brainstem and spinal cord are referred to as the lower motor neuron 
syndrome, and would be characterized by weakness of the affected muscles, loss of reflexes, loss 
of muscle tone, and atrophy [21,22]. These signs would be seen in conditions such as spinal 
muscular atrophy, focal peripheral nerve injury, and generalized neuropathies.  MS is a central 
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nervous system disorder and thus only results in impairment and disability secondary to UMN 
dysfunction. 
1.03 Fatigue in the Neuromuscular System  
The neuromuscular system is a complex system that provides humans with movement, 
from respiration and saccadic movements of the eye, to walking and standing [19,23]. The 
peripheral component of the neuromuscular system, also known as the lower motor neuron, is 
comprised of the alpha motor neurons and peripheral motor axons, which innervate and control 
skeletal muscle fibres. Motor neurons are responsible for relaying signals from the peripheral 
motor system, along the motor pathway, to the skeletal muscle which initiates contraction [24]. 
Muscle fibres are then responsible for contracting, thus generating the torque necessary for 
movement [24]. Muscular fatigue, or fatigability, results from a reduction in muscle torque 
production following exertion [25–27]. This may occur at various sites along the motor pathway 
from the brain and spinal cord to the muscle itself. Since multiple sites are involved in the 
development of neuromuscular fatigue, they can be divided into the CNS and peripheral nervous 
system (PNS). Changes in the CNS or the PNS both contribute to the reduction in muscle torque 
production [28,29].  
Central fatigue results from the inability of the CNS to adequately drive the muscle to 
produce torque during a muscular contraction [30]. It can originate from various sites along the 
motor pathway, and can therefore result from either a reduction in central drive (central 
activation) or modulations to the central drive at the level of the spinal cord [26,31]. During a 
fatiguing task, the CNS increases its central drive to overcome fatigue [32]. Despite an increase 
in central drive, torque production decreases progressively with fatigue [33]. This is referred to 
as central fatigue, and can be identified using variants of  the twitch interpolation technique 
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[25,34–36]. Central fatigue has been demonstrated in several muscle groups of both healthy and 
patient populations, including elbow flexors, quadriceps and ankle dorsi- and plantar-flexors for 
sustained, intermittent, maximal or submaximal voluntary contractions. Using electrical 
stimulation, an estimate that 12% and 20% of the loss of strength during maximal voluntary 
isometric contractions (MVIC) of the elbow flexors and of the ankle dorsiflexors are due to 
central fatigue, respectively [6,26,37]. Furthermore, several transcranial magnetic stimulation 
(TMS) studies have shown that central fatigue can account for over 25% of the reduced torque 
seen during sustained, maximal contractions [38–40]. However, central fatigue appears to 
contribute more significantly to the reduced torque during low-intensity exercise [38]. For 
example, it has been suggested that low-torque, long-duration contractions are more likely to 
lead to the development of central fatigue than high-torque, short-duration contractions 
performed by the same muscle group [41]. In fact, Sogaard et al [42] have indicated through the 
use of TMS, that 40% of fatigue can be attributed centrally during a submaximal (15% MVIC) 
contraction of the elbow flexors until exhaustion.  
Peripheral fatigue, results from loss of muscular torque that occurs at or distal to the 
neuromuscular junction [30]. This can be thought of as fatigue within the peripheral nerve or 
muscle itself [30]. It is also referred to as peripheral fatigue because changes occur within the 
PNS as opposed to the CNS [31]. Schillings et al [43] demonstrated a significant difference in 
voluntary torque before and after a fatiguing task. Their findings suggest a large peripheral 
contribution to fatigue, accounting for 89% of the voluntary force loss after a 2-minute sustained 
MVC. Gandevia et al [33] and Kent-Braun and Le Blanc [6] reported a 26% and 80% loss of 
voluntary torque after a sustained voluntary contraction, respectively, attributing it to peripheral 
factors. Furthermore, Sharma et al [35] found excessive decline in tetanic torque during 
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peripheral nerve stimulation, along with the greater metabolic changes (reduction in phosphorus 
energy metabolites and pH) in individuals with MS. These findings indicate that the source of 
excessive fatigue was peripheral rather than central.  
1.04 Fatigue in MS 
Many of the tasks that we perform during our everyday activities, such as walking up a 
flight of stairs, shopping, or simply getting up from a chair, become increasingly difficult as a 
result of fatigue. In fact, adults with MS report fatigue as their most disabling symptom, affecting 
up to 90% of the MS population [44]. However, despite its high prevalence, fatigue in MS 
remains poorly understood [45]. The term fatigue has been used to describe a multitude of 
physical and cognitive complaints [27,34,46]. As reported by patients, fatigue typically refers to 
a state of exhaustion or tiredness [9,27,47–50]. Factors such as weakness, pain, sleep 
disturbance, and mental illness (depression) all potentially contribute to the increased level of 
fatigue [23,27,51–54]. Fatigue can also be manifested as muscular fatigue or fatigability, and can 
be described as the magnitude of change in the physical performance over a period of time 
[27,55–57]. Therefore, fatigue can be subjectively evaluated with self-report fatigue scales, or 
objectively evaluated with quantitative parameters, such as a reduction in peak torque [34,47]. 
Earlier studies that investigated the interrelationship between fatigability and the 
physical, cognitive and psychosocial complaints of fatigue in individuals with MS, reported no 
relation between symptomatic fatigue, central activation, muscle weakness, or any other clinical 
function measure, including fatigability [35,49,58,59]. Sharma et al [35] studied the extent to 
which fatigability was related to clinical status and symptomatic fatigue. Fatigue was examined 
in 42 participants by measuring muscle torque (MVIC), muscle activation (compound muscle 
action potential), and energy metabolism (phosphorus energy metabolites and pH) of the tibialis 
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anterior muscle, as well as a self-report fatigue questionnaire (FSS) [35]. The main findings of 
the study showed excessive decline in tetanic torque during peripheral nerve stimulation in 
individuals with MS, as well as a positive correlation between fatigability and UMN dysfunction 
and metabolic changes during exercise, but not with symptomatic fatigue ratings [35]. Van der 
Werf et al [59] studied the extent to which cerebral abnormalities, as indicated by white matter 
lesions on magnetic resonance imaging (MRI), had any relation with the severity of fatigue 
complaints of individuals with MS. Forty-five participants rated fatigue severity through a self-
report fatigue questionnaire (Checklist Individual Strength-Fatigue) and the use of a 2-week 
diary, while the MRI provided measures for cerebral abnormalities (white matter lesion load, 
brain atrophy) [59]. These findings suggested no relation between symptomatic fatigue in 
individuals with MS and the extent of cerebral abnormalities, nor to the extent of MRI 
abnormalities in discrete cerebral areas [59].   
Conversely, later studies using self-report fatigue scales and sustained maximal and 
submaximal contractions confirm a relation between symptomatic fatigue and fatigability 
[28,60]. These findings suggest that a combination of complaints is necessary to explain MS-
related fatigue [28,60]. Steens et al [28] investigated associations between symptomatic fatigue 
and measure of fatigability, while correcting for muscle torque. Fatigue was examined in 40 
participants by measuring muscle torque (MVIC), muscle activation (ITT), and corticospinal 
integrity (TMS) during electrical stimulation of the first dorsal interosseous muscle, as well as 
self-report fatigue questionnaires (FSS and HADS). The main results demonstrated a strong 
association between symptomatic fatigue in individuals with MS and the decline in torque during 
an MVIC, as well as measures of voluntary activation [28]. Wolkorte et al [60] took previous 
research one step further and evaluated the robustness of the association between symptomatic 
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fatigue, depression scores, and muscle fatigability in individuals with MS [60]. Fatigue was 
examined in 100 participants by measuring muscle torque (MVIC) of the index finder abductor, 
as well as self-reported fatigue questionnaires (FSS, MFIS, and HADS) [60]. Wolkorte et al [60] 
reported a strong association between symptomatic fatigue and the combination of depression 
and muscle fatigability in individuals with MS [60].  
 
1.05 Quantifying Fatigue in MS  
A great deal of attention in the past 20 years has been focused on the accurate 
identification and measurement of fatigue [61]. Several methods have been developed to assess 
fatigue due to the broad range of underlying mechanisms and confounding factors associated 
with it [62]. A multidimensional approach incorporating both subjective evaluation and torque 
measurements is most useful for a comprehensive analysis when studying fatigue in individuals 
with MS [27,63,64]. 
Measurement of subjective evaluation typically requires the use of self-reported scales 
[1,65–67]. Both the Modified Fatigue Impact Scale (MFIS) and Fatigue Severity Scale (FSS) 
have rapidly become the most widely used tools in MS, clinically [61,68]. Using a Likert-scale 
format, the MFIS is a 21 item questionnaire that quantifies the subjective experience of fatigue 
by addressing the constructs of physical, psychosocial and cognitive fatigue [1,61,66]. The FSS 
is a nine item questionnaire that quantifies the subjective impact and severity of fatigue 
[1,10,67]. In addition, the Visual Analogue Fatigue Scale (VAFS) is a one item questionnaire 
that evaluates the subjective perception of global fatigue experienced in MS [69].  
Objective evaluation of fatigue typically requires the use of torque for its measurement. 
The most direct way of objectively quantifying fatigue involves measuring the change in torque 
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production through the use of a dynamometer [70–72]. This can be achieved by attempting a 
sustained maximal voluntary isometric contraction (MVIC), or a submaximal voluntary 
isometric contraction held to the limit of endurance [26,71,72]. Isometric contractions are 
defined by the production of increasing tension with a constant muscle length or joint angle. 
Measuring percentage drop of initial torque within a predetermined time has been used to 
facilitate group comparisons in special population studies [73,74]. Another way to objectively 
quantify fatigue involves measuring the extent of voluntary activation (VA) through twitch 
interpolation [26,39,75]. The underlying principle involves electrically stimulating the 
appropriate peripheral nerve or muscle at the point of maximal voluntary torque production [25]. 
If central activation is inadequate, the stimulation will evoke additional torque from the muscle 
[30]. The size of the additional torque is proportional to the central drive and number of inactive 
motor units that are not being maximally driven [25]. A decrease in activation, as can occur 
during a sustained contraction, can contribute to the development of fatigue [25].  
Voluntary activation can be determined using the interpolated twitch technique and calculated 
according to Equation 1 [28].   
 
𝑉𝐴 (%) = ( 1 − ( 
𝐼𝑛𝑡𝑒𝑟𝑝𝑜𝑙𝑎𝑡𝑒𝑑 𝑡𝑤𝑖𝑡𝑐ℎ
𝑃𝑜𝑡𝑒𝑛𝑡𝑖𝑎𝑡𝑒𝑑 𝑡𝑤𝑖𝑡𝑐ℎ
)) x 100 (1). 
 
Interpolated twitch represents the maximal torque stimulated using a supramaximal 
stimulus during an MVIC. Potentiated twitch represents the torque using the same supramaximal 
stimulus following the MVIC, while the muscle is at rest [76].   
Applying a fatigue protocol that incorporates changes in torque as the primary outcome 
measure provides a logical approach to objectively compare fatigue in individuals with MS. 
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Quantitative indicators of muscle weakness may provide direct evidence of neuromuscular 
fatigue in MS. Alternatively, objective measurements of fatigue might provide indirect evidence 
of subjective fatigue in individuals with MS.  
1.06 Anatomy 
When investigating fatigue and neuromuscular health, the physiology and function of the 
muscle must be considered. Flexors in the lower limbs, such as the ankle dorsiflexor muscles, 
tend to be more affected in MS due to the upper motor neuron patterns of weakness.  
Literature studying muscle strength in MS reports an increase in muscle weakness and a 
reduction in muscle strength, specific to knee extensors [34,73,77,78], knee flexors [73,79], and 
ankle DF [58] muscle groups. Similarly, muscles of the lower extremities demonstrate a greater 
degree of muscle weakness compared to muscles of the upper extremities [74]. For the study of 
muscular fatigue in individuals with MS, muscles of the lower extremities that are particularly 
active during ambulation are most relevant. For the present investigation, the ankle DF muscles 
of the lower extremities have been selected due to their specific role in mobility and ankle 
stabilization during every day activities, such as walking or climbing up a flight of stairs [80].  
The anterior compartment of the leg consists of muscles that dorsiflex the foot and extend 
the toes. These muscles include the tibialis anterior (TA), extensor hallucis longus, extensor 
digitorum longus and fibularis tertius. The TA is a long, thick muscle against the lateral surface 
of the tibia [81]. It originates on the lateral condyle and body of the tibia and interosseous 
membrane (sheet of fibrous tissue that holds shafts of tibia and fibula together) and inserts onto 
the first metatarsal and medial cuneiform [81,82]. The extensor hallucis longus is a thin muscle 
between the TA and extensor digitorum longus muscles [81]. It originates on the anterior surface 
of the fibula and interosseous membrane and inserts onto the distal phalanx of the great toe [81]. 
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The extensor digitorum longus originates on the lateral condyle of the tibia, anterior surface of 
the fibula, and interosseous membrane and inserts onto the middle and distal phalanges of toes 2-
5 [81]. Lastly, the fibularis tertius muscle is part of the extensor digitorum longus, with which it 
shares a common origin, and inserts onto the base of the fifth metatarsal [81]. Innervated by the 
peroneal nerve, the ankle DF muscles serve to dorsiflex the foot at the ankle joint, invert 
(supination) and evert (pronation) the foot at the intertarsal joints, and extension of toes 1-5 
[81,82]. The dorsiflexor muscles of the leg are displayed in figure 1.3.  
 
Figure 1.3. Dorsiflexor muscles of the leg (with permission from Alexandra Lynette-Krech, 
(2017)) 
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The overall purpose of this thesis was to objectively evaluate the interrelationship between 
symptomatic fatigue and fatigability in individuals with MS. 
 
Objectives 
1. To compare dorsiflexor isometric strength in individuals with MS and healthy individuals 
2. To compare voluntary activation in individuals with MS and healthy individuals 
3. To compare fatigability in individuals with MS and healthy individuals 
4. To compare 6-Minute Walk Times in individuals with MS and healthy individuals 
5. To measure subjective perception of fatigue in individuals with MS and healthy 
individuals using the Modified Fatigue Impact Scale, Fatigue Severity Scale, and Visual 
Analogue Fatigue Scale 
6. To measure fatigue severity and fatigability in individuals with MS and healthy 
individuals through the use of fatigue questionnaires and submaximal isometric testing  
 
Hypotheses 
 
1. Individuals with MS will show decreased dorsiflexor isometric strength in comparison to 
healthy individuals 
2. Individuals with MS will show decreased voluntary activation in comparison to healthy 
individuals 
3. Individuals with MS will exhibit greater fatigue in comparison to healthy individuals 
4. Individuals with MS will have a reduced 6-Minute Walk time in comparison to healthy 
individuals 
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5. Individuals with MS will show higher subjective ratings of fatigue in comparison to 
healthy individuals  
6. Individuals with a higher subjective rating of fatigue will experience greater muscle 
fatigue  
7. The Modified Fatigue Impact Scale and the Fatigue Severity Scale scores will negatively 
correlate with muscle fatigue   
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CHAPTER 2 
 
QUANTITATIVE ASSESSMENT OF MUSCLE STRENGTH AND FATIGUE IN 
INDIVIDUALS WITH MS   
 
2.0 INTRODUCTION 
Individuals with multiple sclerosis (MS) characteristically present fatigue as one of their 
most prevalent and disabling symptoms [1–3]. It has been suggested that up to 95% of 
individuals with MS are affected by fatigue, and that it creates a major impact on quality of life 
and overall well-being [2,3]. The term fatigue can be expressed by various combinations of 
physical, emotional or cognitive complaints [1,4]. It can be described by individuals as a feeling 
of exhaustion [5–7] or lassitude, [8,9] or from a neuromuscular standpoint, it can be described as 
an inability to sustain a required or expected torque [8,10].  
Fatigue remains a challenging symptom for individuals with MS and their care providers 
[11]. Due to its complexity, quantifying muscle fatigue is essential when attempting to fully 
understand the underlying causes. Self-report scales that can broadly be classified as measuring 
subjective fatigue, have emerged as preferred tools clinically [12,2,13]. In addition, objective 
measurements have been employed to quantify the decline in muscle torque during a fatigue-
inducing task [8,12,14-18]. While it has been established that changes in both central and 
peripheral fatigue play a large role in the decline of muscle torque, it is possible to determine 
whether central fatigue or weakness is present during a fatigue-inducing task [8]. The simplest 
approach to determining this is to deliver a supramaximal electric stimulus to the motor nerve 
and to look for a twitch superimposed on the torque produced during a maximal voluntary 
isometric contraction (MVIC) [8,19,20]. Greater recruitment and central drive leaves fewer 
inactive motor units to be stimulated by the superimposed stimulus, yielding a smaller torque 
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recording, or a greater voluntary activation [21]. This commonly used technique is known as 
twitch interpolation and has been applied to various clinical and special populations such as knee 
osteoarthritis [21], chronic fatigue syndrome [22], amyotrophic lateral sclerosis [23], adult aging 
[24], and more.  
Studies investigating voluntary activation (VA) [25–28,16,29] reported that individuals 
with MS have impaired central activation during both non-fatiguing and fatiguing motor tasks 
compared to healthy individuals. A study by Steens et al [25] reported that muscle fatigue was 
strongly associated with a decline in central activation during a fatiguing task of the first dorsal 
interosseous. Studies investigating direct muscle torque [25,30,27,29] reported that individuals 
with MS are significantly weaker than healthy individuals during a MVIC. Using surface EMG, 
van der Kamp et al [31] found MVICs of the thenar muscles were 40% weaker in individuals 
with various courses of MS.  
Researchers continues to investigate the interrelationship between symptomatic fatigue 
and fatigability [5,32]. Earlier studies [5,7] showed no association between symptomatic fatigue 
in individuals with MS and objective measures of fatigability, while later studies [25] found a 
stronger association. The differences in these findings between symptomatic fatigue and 
fatigability might be specific to the methodology used. Therefore, a multidimensional approach 
used to study both the subjective (self-report scales) and objective (direct muscle torque) 
components of fatigue will provide a viable framework to study muscle strength and fatigue in 
individuals with MS [1]. 
The aim of this study was to objectively investigate the role of muscle strength and 
voluntary activation on symptomatic fatigue in individuals with MS. The muscle group chosen 
for this study was the ankle dorsiflexor (DF) muscles because of their specific role in mobility 
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and ankle stabilization when performing every day activities. Furthermore, weakness in the 
flexors of the lower limbs, such as DF muscles tend to be more common in individuals with MS 
due to upper motor neuron patterns of weakness. We hypothesize that individuals with MS who 
are experiencing fatigue will exhibit deficits in muscle strength and voluntary activation. 
Additionally, quantitative indicators of muscle weakness and fatigue may provide indirect 
evidence of symptomatic fatigue.  
 
2.1 METHODS 
2.1.1 Study Participants  
A schematic representation of the study protocol is included in Figure 2.1. Eighteen 
participants (nine women with relapsing-remitting MS (RRMS) or secondary-progressive MS 
(SPMS) and nine healthy aged matched women; ages 20-60 years) were invited to participate in 
the study. Participants’ health was determined through the inclusion/exclusion criteria of the 
study protocol as well as informal screening prior to commencement of the study. All 
participants were otherwise healthy with no self-reported neuromuscular or musculoskeletal 
disorders that would affect their gait or ability to perform strong muscle contractions in the lower 
leg. RRMS/SPMS participants were recruited and screened using an Expanded Disability Status 
Scale (EDSS) [33] (Appendix A) by Dr. S. Morrow, an experienced neurologist from the London 
Health Science Centre MS Clinic. Participants with an EDSS score between 2.0-6.5 were eligible 
to partake in the study. Healthy participants were recruited from the Western University student 
population, as well as the London community. All participants provided informed written 
consent and the study was approved by Western University, Health Sciences Research Ethics 
Board (Appendix F).  
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Figure 2.1. Schematic representation of the study protocol  
 
2.1.2 Measures of Fatigue  
All data was collected during a single visit to the Neuromuscular Performance Laboratory 
at Parkwood Institute (London, Ontario). At the beginning of the visit, participants completed the 
Modified Fatigue Impact Scale (MFIS) [34,36] (Appendix B), Fatigue Severity Scale (FSS) 
[34,35] (Appendix C), Visual Analogue Fatigue Scale (VAFS) [35] (Appendix D) and a 6-
Minute Walk Test (6MWT) [37] (Appendix E).   
The MFIS is a 21-item self-administered questionnaire used to assess the perceived 
impact of fatigue within the past four weeks, and is aggregated into physical, cognitive and 
psychosocial domains [34,38,12]. Participants rate on a 5-point Likert scale 0 being ‘never’ to 4 
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being ‘almost always’, the extent to which they feel the statement applies to them. A total sum 
score out of 84 is calculated, with higher scores indicating a greater impact of fatigue.  
The FSS is a 9-item self-administered questionnaire used to assess the severity of fatigue 
and the impact on daily functioning during the past week [34,38,12,39]. Participants indicate on 
a 7-point Likert scale 1 being ‘strongly disagree’ to 7 being ‘strongly agree’, the extent to which 
they feel each statement applies to them. A total sum score out of 63 is calculated, with higher 
scores indicating a greater impact of fatigue.  
The VAFS is a one-item questionnaire used to assess the participants’ global fatigue. 
Participants rate on a 10-point Likert scale 0 being ‘worst’ to 10 being ‘normal’, the extent to 
which they feel the statement applies to them. A total sum score out of 10 is calculated, with 
lower scores indicating an increase in fatigue severity.  
 Following completion of the fatigue questionnaires, participants were required to 
complete a 6MWT. Procedures were adopted from the American Thoracic Society guidelines. 
Participants were able to use assistive devices if needed, while walking a 26 meter linear course, 
marked by 2 meter increments. Participants were instructed to walk as fast as possible along the 
marked course, turn around at the last marker, return to the start, and repeat this course as often 
as possible in six minutes. The time elapsed was measured with a stopwatch, and the distance 
walked per minute was measured and summed for total distance in meters. Verbal 
encouragement was provided and a scripted text was used to provide guidance before, during, 
and after the six minutes. 
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2.1.3 Measurement of Isometric Strength and Fatigue 
Participants were seated upright in the ankle dynamometer (McComas and Belanger 
1981) with their right ankle positioned at 30° plantar flexion and hip and knee angles of 90°. 
Velcro straps were fastened across the participant’s foot (Figure 2.2). Additionally, during all 
contractions, participants were instructed to fold their arms across the chest to avoid extraneous 
movement.  
The test protocol commenced with a series of submaximal isometric contractions for the 
purpose of warm-up and familiarization. Participants then performed repeated (3-5 repetitions), 
brief (~ 5s) MVICs of the ankle DF, each separated by 2 minutes of rest. Maximal torque was 
attained when two consecutive MVICs differed by less than 5%. Participants were provided with 
strong verbal encouragement. Torque was displayed in real-time on an online system using the 
Spike 2 software in attempt to obtain maximal effort.   
The fatigue protocol consisted of a sustained submaximal voluntary isometric contraction 
(50% MVIC) held to the limit of endurance. Torque produced by each participant and two lines 
identifying the target torque (50% MVIC) and cut off torque level (40% MVIC) were displayed 
using Spike 2 software. Task termination resulted when the participants torque dropped below 
the 40% MVIC line twice and the time to task failure (TTF) in seconds was recorded. 
Immediately following task termination, participants completed one final MVIC of the ankle DF 
muscles, while the study examiner manually delivered an electrical stimulation ~ 1s prior, during 
maximal plateaued torque, and ~1s following their maximal contraction. To score global fatigue, 
the ratings of VAFS were requested from the participants following fatiguing task.  
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2.1.4 Measurement of Voluntary Activation 
Voluntary activation  
Participants were seated upright in the ankle dynamometer (McComas and Belanger 
1981) with their right ankle positioned at 30° plantar flexion and hip and knee angles of 90°. 
Velcro straps were fastened across the participant’s foot (Figure 2.2). Additionally, during all 
contractions, participants were instructed to fold their arms across the chest to avoid extraneous 
movement. 
To obtain the maximal twitch torque, electrical stimulation was applied to the peroneal 
nerve around the fibular head with a constant current stimulator (DS7AH, Digitimer, UK). A series 
of incremental stimuli of increasing intensity were delivered to the resting muscle. Once the 
torque output reached a plateau, the stimulus was deemed maximal. The stimulus was then 
increased an additional ~10% to achieve supramaximal stimulation.  
The test protocol commenced with a series of submaximal isometric contractions for the 
purpose of warm-up and familiarization. Participants then performed brief (~ 5s) MVICs of the 
ankle DF muscles. A single supramaximal stimulus was applied to the peroneal nerve prior to 
their MVIC. A second supramaximal stimulus was applied at the point of maximal voluntary 
torque, which was visually determined as the point of torque plateau. A third single 
supramaximal stimulus was delivered at rest ~1s following their MVIC to obtain the potentiated 
twitch. This procedure was repeated 3-4 times for each participant, followed by 2 minutes rest 
between trials.  
A standard equation (VA (%) = (1 – (interpolated twitch /potentiated twitch)) x 100 was 
used to calculate the percent of VA. VA is considered maximal when there is no superimposed 
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twitch evoked at the peak of the MVIC in response to the supramaximal stimulation of the 
peripheral nerve.  
 
 
Figure 2.2. Schematic representation of the experimental setup (with permission from 
Alexandra Lynette-Krech, (2017))  
 
 
2.1.5 Statistical Methods 
All analyses were performed using Statistical Package for the Social Sciences (Version 
24; IBM SPSS Inc., Chicago, IL). Data was testing for normal distribution using the Shapiro-
Wilk Test. A two-tailed independent samples t-test was used to identify any differences between 
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groups for demographic data, fatigue-scaled scores, 6-MWT, MVIC, VA, and TTF. The 
association between the dependent variables, such as the MFIS, FSS and VAFS, and the different 
measures of MVIC, VA, 6-MWT, and TTF as the independent variables were determined using 
Pearson's correlation analysis. A split-plot analysis of variance (group by time) was performed to 
investigate a potential interaction for MS participants versus healthy controls at baseline and 
post-fatigue on MVIC, VA and VAFS scores. If a significant interaction was detected, a Tukey 
post hoc analysis was performed to determine where the differences existed. A significance level 
of p≤0.05 was used for all statistical tests. All values are reported in mean ± standard deviation 
(SD).  
 
2.2 RESULTS   
2.2.1 Demographics  
Subject characteristics are present in Table 1. Participants ranged in age from 22 to 60 
years, with an average age of 39 years (SD= 10 years). No difference was observed in age 
between the MS group and healthy controls. The majority of participants were of Caucasian 
descent, with the exception of one African Canadian participant belonging to the MS group. 
According to international classification standards for body mass index (weight (kg) / height 
(m)2), on average, both groups were slightly overweight (BMI ≥ 25). EDSS scores for the MS 
group ranged from 2.0 to 6.5 points, with an average of 4 points (SD= 2 points). The majority of 
MS participants were currently taking DMTs as a part of their MS treatment regime. A brief 
history of diagnosis date as well as current treatment are displayed in Table 2. 
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Table 1. Subject Characteristics  
Group n Age (years) 
mean ± SD 
BMI 
mean ± SD 
EDSS 
mean ± SD 
 
Control 
 
9 
 
35 ± 7 
 
25 ± 3 
 
n/a 
 
MS 
 
9 
 
43 ± 11 
 
27 ± 4 
 
4 ± 2 
BMI= body mass index, EDSS= expanded disability status scale.  
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Table 2. History of MS Participants  
Code Dx Treatment 
MS 01 
MS 02 
MS 03 
MS 04 
MS 05 
MS 06 
MS 07 
MS 08 
MS 09 
2011 
2012 
2009 
2017 
2004 
2009 
2011 
1994 
2010 
Rebif 
None 
None 
Aubagio 
Copaxone 
Tysabi 
None 
None 
Aubagio 
Dx = date of diagnosis 
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2.2.2 Fatigue Questionnaires and 6-MWT 
An overview of scores resulting from the MFIS, FSS and VAFS are included in Table 3. 
According to the MFIS, the MS group experienced more fatigue compared with healthy controls 
(p<0.05). Distance walked during the 6-MWT (r= -0.720, p= 0.001) (Figure 2.4), baseline MVIC 
torque (r= -0.689, p= 0.002), post-fatigue MVIC torque (r= -0.666, p= 0.003), and baseline VA 
(r= -0.589, p= 0.010) scores were all negatively associated with MFIS scores. No association 
was found between MFIS scores and post-fatigue VA and TTF scores.  
The MS group experienced more physical fatigue compared with healthy controls 
(p<0.05). A negative association was observed between MFIS physical scores and distance 
walked during the 6-MWT (r = -0.659, p= 0.003), baseline MVIC torque (r = -0.641, p = 0.004), 
post-fatigue MVIC torque (r = -0.541, p = 0.020), and baseline VA (r = -0.609, p = 0.007) 
scores. These findings suggest that the higher ratings of perceived physical fatigue were 
associated with lower activation and strength of the DF muscles. No association was found 
between MFIS physical scores and post-fatigue VA and TTF scores.  
Like physical fatigue scores, the MS group experienced more cognitive fatigue compared 
with healthy controls (p<0.05). Distance walked during the 6-MWT (r = -0.477, p = 0.045), 
baseline MVIC torque (r = -0.498, p = 0.036), post-fatigue MVIC torque (r = -0.596, p = 0.009), 
and post-fatigue VA (r = -0.504, p = 0.033) scores were all negatively associated with MFIS 
cognitive scores. No correlation was found between MFIS cognitive scores and baseline VA and 
TTF scores.  
MFIS psychosocial scores did not differ between groups (p>0.05). However, MFIS 
psychosocial scores were negatively associated with distance walked during the 6-MWT (r = -0 
 34 
.628, p = 0.005). No association was found between MFIS psychosocial scores and MVIC, VA, 
and TTF scores.  
No difference was observed in FSS scores between the MS group and healthy controls 
(p>0.05). However, the FSS was negatively associated with distance walked during the 6-MWT 
(r = -0.731, p = 0.001), indicating higher ratings of perceived fatigue were accompanied by 
shorter distance walked. No association was found between FSS scores and MVIC torque, VA, 
and TTF scores.  
Results from the 2-item VAFS indicated no difference between groups or scores 
(p>0.05). In addition, disability status (EDSS) showed a significant association with FSS (r = 
0.687, p = 0.041) scores but not with MFIS scores.   
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Table 3. Fatigue Scales 
Group MFIS 
Total 
mean ± SD 
range 
MFIS 
physical 
mean ± SD 
range 
MFIS 
cognitive 
mean ± SD 
range 
MFIS 
psychosocial 
mean ± SD 
range 
FSS 
Total 
mean ± SD 
range 
Baseline 
VAFS 
mean ± SD 
range 
Post-fatigue 
VAFS 
mean ± SD 
range 
 
Control 
 
31 ± 9 
22 to 49 
 
13 ± 4 
7 to 20 
 
15 ± 4 
11 to 24 
 
3 ± 2 
1 to 6 
 
 
31 ± 12 
14 to 49 
 
8 ± 1 
6 to 9 
 
 
8 ± 1 
7 to 9 
MS  51 ± 14* 
32 to 79 
 26 ± 12* 
10 to 35 
21 ± 6* 
9 to 30 
4 ± 2 
2 to 7 
42 ± 11 
18 to 53 
 
7 ± 2 
4 to 10 
7 ± 2 
4 to 10 
 
MFIS = modified fatigue impact scale, FSS = fatigue severity scale, VAFS = visual analogue 
fatigue scale. * Indicates a significant difference between controls and MS. 
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2.2.3 Force Measurement and Fatigue Test 
As shown in figure 2.3, the MS group walked a shorter distance compared with healthy 
controls during the 6-MWT (p<0.001). A positive relation was found between distance walked 
and baseline MVIC torque (r = 0.547, p = 0.019) scores, indicating that increased distance 
walked was associated with increased MVIC torque.  
Baseline and post-fatigue scores on MVIC, VA, 6-MWT, and TTF are outlined in Table 
4 and Table 5, respectively. The average strength (MVIC) for healthy controls was 26.06 ± 3.33 
Nm, which was significantly stronger than the MS group who had an average MVIC of 18.61 ± 
7.33 Nm (p<0.05). As shown in Figure 2.5, when normalized to participants’ body mass (BM), 
healthy controls had greater MVIC torque scores compared with the MS group at baseline and 
post-fatigue testing (p<0.05). Both groups MVIC torque decreased post-fatigue (p<0.05). There 
was no interaction between participants (MS and healthy controls) and MVIC torque (F (1,16) = 
0.94, p>0.05) at baseline and post-fatigue testing. There was a main effect on MVIC torque 
within participants (F(1,16) = 37.60), p<0.001), as well as between groups (F(1,16) = 18.97, 
p<0.001). As shown in figure 2.6, healthy controls had greater VA scores compared with the MS 
group at baseline and post-fatigue testing (p<0.05). There was no interaction between participants 
(MS and healthy controls) and VA (F(1,16) = 9.34, p>0.05) scores at baseline and post-fatigue 
testing. There was a main effect on VA scores between groups (F(1,16) = 9.34, p<0.05). A 
positive association was observed between MVIC torque and VA scores at baseline, indicating 
that lower MVIC torque was accompanied by lower VA levels (r = 0.607, p = 0.008; r = 0.743, p 
= 0.001, respectively).  
As shown in Figure 2.7, no difference was found in average TTF scores between the MS 
group and healthy controls (p > 0.05). 
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Table 4. Baseline Quantitative Parameters  
Group Baseline MVIC  
(Nm) 
mean ± SD 
Baseline MVIC 
(Nm/kg BM) 
mean ± SD 
6-MWT 
(m) 
mean ± SD 
Baseline VA 
(%) 
mean ± SD 
 
Control 
 
26.0 ± 3.33 
 
0.39 ± 0.06 
 
458 ± 63 
 
95 ± 2 
 
MS 
 
18.6 ± 7.33* 
 
0.25 ± 0.07* 
 
312 ± 85* 
 
76 ± 23* 
* Indicates a significant difference between healthy controls and MS participants. 
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Table 5. Post-fatigue Quantitative Parameters  
Group TTF 
(s) 
mean ± SD 
Post-fatigue MVIC  
(Nm/kg BM) 
mean ± SD 
Post-fatigue VA  
(%) 
mean ± SD 
 
Control 
 
149 ± 69 
 
0.30 ± 0.06 
 
95 ± 4 
 
MS 
 
118 ± 31 
 
0.19 ± 0.07* 
 
78 ± 17* 
* Indicates a significant difference between healthy controls and MS participants. 
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Figure 2.3. Distance walked during the 6-minute walk test 
 
Distance walked (m) during the 6-MWT for healthy controls (black) and MS participants (grey). 
Distance walked was significantly shorter in the MS group (p<0.05). Values are presented as 
means ± SD. * Represents a significant difference between healthy controls and MS participants. 
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Figure 2.4. Correlation between 6-minute walk times and MFIS scores  
 
A strong correlation exists between distance walked during the 6-minute walk test and MFIS 
scores (r = 0.720, p = 0.001) in healthy controls (black) and MS participants (grey).
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Figure 2.5. Strength of the DF muscles 
 
Peak torque (Nm/kgBM) of the DF muscles normalized to subjects’ BM of healthy controls 
(black) and MS participants (grey). MS participants were significantly weaker than healthy 
controls (p<0.05). Both groups decreased torque post-fatigue (p<0.05). Values are presented as 
means ± SD.  Represents a significant effect within healthy controls and MS participants.         
* Represents a significant effect between healthy controls and MS participants. 
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Figure 2.6. Voluntary activation of the DF muscles 
 
Voluntary activation (%) of the DF muscles for healthy controls (black) and MS participants 
(grey). Voluntary activation was significantly lower in MS participants at baseline and post-
fatigue testing (p<0.05). Values are presented as means ± SD.  * Represents a significant effect 
between healthy controls and the MS participants. 
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Figure 2.7. Time to task failure 
 
Time to task failure (s) during submaximal contraction of the DF muscles held to the limit of 
endurance for healthy controls (black) and MS participants (grey). No difference was observed 
between groups (p>0.05). Values are presented as means ± SD.
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2.3 DISCUSSION 
The study assessed the impact of muscle strength and voluntary activation on 
symptomatic fatigue in individuals with MS. It was hypothesized that individuals with MS would 
exhibit 1) reduced muscle strength and voluntary activation, which would correlate to 2) a higher 
symptomatic fatigue rating, 3) greater fatigability on an objective test of neuromuscular fatigue 
and 4) a reduced 6-minute walk time. The main findings demonstrated that individuals with MS 
have reduced muscle strength, voluntary activation, and 6-minute walk times compared with 
healthy controls. Individuals with MS reported higher levels of symptomatic fatigue, which were 
strongly associated with normalized peak torque and voluntary activation for DF muscles. No 
relation exists between symptomatic fatigue and fatigability. 
 As fatigue is a predominant characteristic of MS, the observation that individuals with 
MS report greater fatigue than healthy controls is well supported by previous research [7,44,20]. 
In the present study, individuals with MS subjectively reported themselves significantly more 
fatigued on the MFIS, FSS and VAFS than healthy controls. A difference in the total MFIS score 
was observed between groups. Furthermore, a significant difference in MFIS physical and 
cognitive scores was observed between groups. However, no difference was observed in 
psychosocial scores. Previous research using self-report scales have indicated a strong 
correlation between total MFIS and FSS scores [34,45]. Consistent with the findings, a strong 
relation existed between MFIS and FSS scores in the present study, however, no difference was 
observed in FSS scores between groups. One possible explanation for the non-significant finding 
in the FSS may be due to the relatively small sample size (N=18), and large group variance in the 
present study. Studies that have reported significant findings incorporated a larger sample size 
(N>100), increasing the power to detect a statistically significant relationship [34,36,46]. In 
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addition, previous studies have shown a stronger relation with depression scores and total MFIS 
scores, compared with FSS scores [34,45,36]. Thus, the MFIS may have been more sensitive to 
the psychological variables that presented in the healthy control group.  
The relationship between decreased muscle strength and a subsequent increase in 
physical inactivity and psychological factors has been determined in individuals with MS 
[34,47]. Despite the well-known benefits of physical activity, it has been established that 
individuals with MS report being less physically active than healthy controls [48,49,38]. 
Engaging in physical activity may further improve cognitive function, fatigue, and quality of life. 
In a study by Trojan et al [51], researchers compared symptomatic fatigue and biopsychosocial 
correlates of fatigue (disease course, physical inactivity, and depression) in 53 individuals with 
MS. One main finding was the association between physical inactivity and increased 
symptomatic fatigue in individuals with MS. The majority of participants in Trojan’s study were 
slightly overweight (B.M.I  ≥  25 ) or obese, potentially contributing to the indirect cause of 
physical activity and subsequently leading to an increased perception of fatigue [51]. Further, 
studies have found significant associations between psychological variables, such as depression 
and fatigue in individuals with MS [3,52]. A longitudinal study by Kinsinger et al [3] examined 
the influence of depression and fatigue on symptomatic cognitive fatigue and neuropsychological 
impairment in a clinical trial. Self-report scales and structured interviews were conducted over 
127 participants with MS. Findings suggest that the treatment of depression and fatigue 
symptoms can influence an individual’s ability to accurately perceive their cognitive 
performance. This study supports previous findings [53–56] by demonstrating the impact of 
depression and symptomatic fatigue on cognitive function [3]. In the present study however, 
behavioural or psychosocial variables were not measured. Through structured conversations, 
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38% of participants in the present study (17% controls, 21% MS) presented a mental illness 
(depression and or anxiety), potentially contributing to the increased symptomatic fatigue 
experienced in both groups. Therefore, the interaction between symptomatic fatigue and muscle 
fatigue merits further investigation. Determining the impact of biopsychosocial variables on 
symptomatic fatigue will offer the opportunity to implement new treatments to reduce 
experienced fatigue in the MS population. 
A primary objective of this investigation was to determine if there were differences in 
muscle strength and activation between individuals with MS and healthy controls. After 
accounting for differences in body mass and age, we found that overall, absolute peak torque was 
36% lower in the MS group than healthy controls. This finding is slightly lower than previous 
research studying similar parameters [25,15,29,30]. A difference in peak torque was observed 
between groups at baseline (pre-fatigue) and immediately following the fatigue task. Following 
the fatigue task, both groups exhibited decreased torque. One explanation for lower torque-
generation in the MS group is the impaired central drive from the CNS to the LMNs of specific 
muscles, such as the DF muscles [57]. It has been reported that when a supramaximal electrical 
stimulus is imposed on the working muscle during a MVIC, there is a large increase in torque in 
individuals with MS. This suggests that individuals with MS have a reduced ability to fully 
activate their muscles [15]. Rice et al [26] have reported that motor neuron firing rates during a 
MVIC are significantly lower in individuals with MS which may indicate reduced central drive. 
In the present study, a strong association was demonstrated between MVIC torque and voluntary 
activation levels, indicating that higher MVIC torques were accompanied by higher voluntary 
activation levels. Furthermore, we used interpolated twitch to measure voluntary activation of the 
DF muscles between the MS group and healthy controls. Complete voluntary activation 
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represents a state in which all motor units are recruited and firing at their optimal rate [58]. 
Several muscles, including muscles of the lower limbs, have demonstrated a reduction in 
voluntary activation following prolonged activity [26,58,59,40]. This decrease in voluntary 
activation has been defined as central fatigue [26,58,59,40]. The mean non-fatigued level of 
voluntary activation in lower limb muscles ranges from 94%-100% in healthy controls. In 
comparison, the mean non-fatigued level of voluntary activation in individuals with MS is quite 
variable, ranging from 47%-93% [60]. Consistent with these findings, in the present study, a 
significantly lower activation was demonstrated in the MS group. The MS group produced a 
mean activation level of 77% versus 96% in healthy controls. This difference could account for 
almost all of the difference observed in MVIC torque scores between groups. The remaining 
difference could be attributed to the changes within the muscle, such as muscle mass or intrinsic 
strength. However, no difference was observed between groups following the fatigue task. One 
possible explanation relates to central and peripheral adaptions during the fatigue task. Following 
prolonged muscle activity, lower limb muscles have demonstrated that the extent to which 
central fatigue develops may be dependent on the task performed [26]. Studies suggest that low-
torque, long-duration contractions are more likely to lead to the development of central fatigue 
than high-torque, short-duration contractions performed by the same muscle group [59]. In a 
study by Behm and St-Pierre [59], two intermittent fatigue tasks were used to examine central 
fatigue in the quadriceps muscle. The contraction intensity largely influences the duration of the 
fatiguing task [59]. The high-torque, short duration fatiguing task consisted of a 50% MVIC 
intensity, while the low-torque, long duration fatiguing task consisted of a 25% MVIC intensity. 
A greater decline in voluntary activation was observed following the low-torque (25%), long 
duration MVIC compared to the high-torque (50%), short duration MVIC. Therefore, the similar 
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times to fatigue in the current study may be dependent on the similar 50% contraction intensity 
of the fatiguing task performed. Further, sample size and variability are two important factors 
that influence the power of a study, such that the greater the sample size and the lower the 
variance, the greater the power. In the present study, a relatively small sample size in addition 
with high variability was observed during the fatiguing task, potentially contributing to a greater 
type II error.   
Significant differences between symptomatic fatigue and measures of fatigability have 
been demonstrated in previous research [29,27,61]. In the present study however, no association 
was observed between symptomatic fatigue and fatigability, as measured by time to task failure. 
Thus, higher MFIS and FSS scores were not correlated to higher muscle fatigability at a 
submaximal intensity. A study by Romani et al [62] examined the relationship between 
symptomatic fatigue and measures of fatigability in individuals with MS. A multidimensional 
assessment tool was used to categorize individuals who experienced high (75th percentile) fatigue 
versus low (25th percentile) fatigue. Fatigability was measured through sustained MVICs of the 
thumb adductors. Results indicated no difference in fatigability between individuals who 
reported experiencing high fatigue versus low fatigue. Similar findings were presented in 
individuals with Chronic Fatigue Syndrome (CFS) [63]. Individuals with CFS reported high 
levels of effort associated with physical activity with no apparent difference in fatigability 
compared with healthy controls [63]. It has been suggested that fatigue in individuals with CFS 
is central in origin resulting from disrupted signaling between normal firing frequency upon 
motor units [64]. Thus, the underlying pathophysiology of fatigue could provide a framework for 
fatigue perceived by individuals with MS.  
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A study by McKenzie and Gandevia [65] provides evidence of a relationship between 
absolute muscle torque and fatigability, suggesting that the greater the absolute torque the more 
quickly the muscle fatigues [65]. In the present study, a lower absolute torque was observed in 
the MS group compared with healthy controls and thus, potentially contributing to greater fatigue 
resistance experienced. The underlying pathophysiology of fatigue in MS may be curtailed by a 
significantly lower absolute torque. Furthermore, studies have reported a greater decline in 
distance walked during the 6-minute walk test in individuals with MS compared to healthy 
controls [66]. The decline in distance walked correlated with greater symptomatic physical 
fatigue and poorer physical function [66]. In the present study, distance walked during a 6-
minute walk test was shorter in the MS group compared with healthy controls. A strong 
association was demonstrated in the 6-minute walk time and MVIC torque, indicating that 
stronger MVIC torques were accompanied by greater distances walked. The 6-minute walk test 
distance also distinguished a relationship between various disability scores on the EDSS and 
distance walked. A higher disability score was associated with a reduced distance walked during 
the 6-minutes compared to lower disability scores in the MS group. These findings were not 
surprising as higher EDSS (4.0-6.5) scores are primarily based upon walking ability. However, 
this observation was not significant. Due to the large difference in distance covered on the 6-
MWT between the MS group and healthy controls, it would be interesting to quantify VA after a 
fatiguing task similar to the 6-MWT. In the present study, fatigability, as measured by time to 
task failure, did not produce a significant difference between the MS group and healthy controls 
but distanced covered on the 6-MWT did.  
In summary, individuals with MS reported higher levels of symptomatic fatigue on the 
MFIS, FSS and VAFS, while demonstrating reduced muscle strength, voluntary activation and 
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distanced covered on the 6-MWT compared with healthy controls. Symptomatic fatigue assessed 
by the MFIS was associated with fatigability, as measured by MVIC torque but not time to task 
failure.  
 
2.4 LIMITATIONS 
It is important to consider the limitations of the present study before applying the findings to 
a broader population of individuals with MS. One limitation of the study was that the sample size 
of each group was relatively small, decreasing the overall power of the study. Although previous 
literature has been able to identify a significant difference between symptomatic fatigue and 
fatigability, a sample size of eighteen participants used in the present study in addition with high 
variability may have contributed to the non-significant results observed in the FSS and TTF 
scores.   
Another limitation in the present study was that MS participants were not severely affected 
by the disease. The study targeted individuals with relapsing-remitting or secondary-progressive 
MS, at a moderate level of disability (EDSS= 4 ± 2). Therefore, it is unknown whether similar 
results may be obtained in a more progressive stage of MS or disabled population.  
Other variables may distort the relationship between symptomatic fatigue and fatigability. 
For example, mental illness, such as depression, is positively associated with fatigue. Through 
structured interview, 38% of participants (17% controls, 21% MS) in the present study reported a 
history of mental illness, possibly contributing to the non-significant result. A more definitive 
study could examine symptomatic variability and consider excluding confounding variables 
including mental illness. 
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Lastly, fatigue is a broad and multidimensional construct. Despite the good psychometric 
properties of the MFIS and FSS, self-reported questionnaires have their acknowledged 
limitations, such as retrospective bias. Therefore, the ability to directly link symptomatic fatigue 
to muscle fatigability in the present study is somewhat limited. A multidisciplinary approach was 
used in the present study to limit this problem, however in a clinical population it is challenging 
to avoid all potentially confounding variables.  
 
2.5 CONCLUSIONS AND FUTURE DIRECTIONS 
In summary, the data presented here demonstrate that individuals with MS have significant 
reductions in distance walked during 6-minutes, peak torque, and voluntary activation of the DF 
muscles compared with healthy controls. Symptomatic fatigue, established from the MFIS, was 
associated with fatigability, as measured by MVIC but not time to task failure. Overall our 
findings provided an introductory contribution to research in quantifying muscle strength and 
fatigue in individuals with MS. Further, MRIs directly measuring muscle mass may contribute to 
greater understanding of mechanisms for muscle weakness and fatigue. Future research in 
quantifying muscle strength and fatigue should emphasize more functionally relevant fatiguing 
tasks, such as the 6-minute walk test or sit to stand tasks. This would allow studies to determine 
how muscle strength and fatigue may impact activities of daily living in individuals with MS. In 
addition, repeating the present study that establishes a sub-group analysis based on disease 
severity, may also yield unique findings. 
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